Contineum Therapeutics, Inc. (CTNM)
NASDAQ: CTNM · Real-Time Price · USD
13.50
+0.15 (1.12%)
Dec 20, 2024, 4:00 PM EST - Market closed
Contineum Therapeutics Employees
Contineum Therapeutics had 31 employees as of December 31, 2023.
Employees
31
Change
n/a
Growth
n/a
Revenue / Employee
n/a
Profits / Employee
-$931,839
Market Cap
348.00M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 31 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| AngioDynamics | 748 |
| Valneva SE | 676 |
| Spok Holdings | 384 |
| Kamada | 378 |
| Sana Biotechnology | 328 |
| Prime Medicine | 234 |
| NeuroPace | 171 |
| Absci | 155 |
CTNM News
- 5 days ago - Contineum Therapeutics Initiates Patient Dosing in Phase 1b Positron Emission Tomography (PET) Trial of PIPE-791 - Business Wire
- 26 days ago - Contineum Therapeutics to Attend the 7th Annual Evercore HealthCONx Conference - Business Wire
- 4 weeks ago - Contineum Therapeutics Expands Clinical Development of PIPE-791 With FDA Authorization of Its Investigational New Drug (IND) Application for Chronic Pain - Business Wire
- 5 weeks ago - Contineum Therapeutics to Attend Upcoming Investor Conferences - Business Wire
- 6 weeks ago - Contineum Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights - Business Wire
- 4 months ago - Contineum Therapeutics to Present at Multiple Upcoming Investor Conferences - Business Wire
- 4 months ago - Contineum Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights - Business Wire
- 5 months ago - Contineum Therapeutics Announces Publication of Encouraging Data in the Proceedings of the National Academy of Sciences on PIPE-307, Its M1 Receptor Selective Inhibitor, in Clinical Development for Relapse-Remitting Multiple Sclerosis - Business Wire